{"ATC Code":"N02AB03","Abbreviation":"","Aliases":["Phentanyl","Fentanil","Durogesic","Fentanila","Fentanylum","Sentonil","Sublimase","Matrifen","Duragesic-100","N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide"],"Biological Half-Life":"The half life of fentanyl is 7  hours. The half life of fentanyl sublingual spray is 5-12 hours.","CAS":"437-38-7","ChEBI":"CHEBI:119915","ChEMBL":"CHEMBL596","ChemicalClasses":["piperidine"],"Chirality":"achiral","Color/Form":"Crystals","Decomposition":"When heated to decomposition it emits toxic fumes of /nitrogen oxides/.","Dosing Info":[{"Method":"Transdermal","Tiers":{"Common":{"Lower":25,"Upper":50},"Heavy":{"Lower":100,"Upper":100},"Light":{"Lower":14.5,"Upper":25},"Strong":{"Lower":50,"Upper":100},"Threshold":{"Lower":2.5,"Upper":14.5}},"Unit":"µg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates","Drug Indication":"Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.  Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.","Drug Warnings":"/BOXED WARNING/ WARNING: RISK OF RESPIRATORY DEPRESSION. Fatal respiratory depression has occurred in patients treated with oral transmucosal fentanyl citrate, including following use in opioid non-tolerant patients and improper dosing. The substitution of oral transmucosal fentanyl citrate for any other fentanyl product may result in fatal overdose. Due to the risk of respiratory depression, oral transmucosal fentanyl citrate is contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients. Death has been reported in children who have accidentally ingested oral transmucosal fentanyl citrate. Oral transmucosal fentanyl citrate must be kept out of reach of children. The concomitant use of oral transmucosal fentanyl citrate with CYP3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression. /Fentanyl citrate lozenge/","DrugClasses":["opioid"],"DurationOfAction":"Intravaneous: 30–60\u0026nbspminutes","EINECS":"207-113-6","EliminationHalfLife":"Intravaneous: 6\u0026nbspmins (T\u003csub\u003e1/2\u003c/sub\u003e α) 1\u0026nbsphours (T\u003csub\u003e1/2\u003c/sub\u003e β) 16\u0026nbsphours (T\u003csub\u003e1/2\u003c/sub\u003e ɣ) Intranasal: 15–25\u0026nbsphours Transdermal: 20–27\u0026nbsphours Sublingual: 5–13.5\u0026nbsphours Buccal: 3.2–6.4\u0026nbsphours","European Community (EC) Number":"207-113-6","FDA Pharmacological Classification":"UF599785JZ","FullSalts":["Fentanyl citrate","Fentanyl hydrochloride"],"HMDB ID":"HMDB0014951","HeavyAtomCount":25,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates","IUPACName":"N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide","Impurities":["norfentanyl","acetylfentanyl","despropionylfentanyl","2-chloro-n-phenyl-n-(1-(2-phenylethyl)piperidin-4-yl)propanamide, (±)-","phenethyl bromide","4-anilinopiperidine","benzylfentanyl","benzaldehyde","n-phenyl-1-(phenylmethyl)-4-piperidinamine","phenethyl-4-anpp"],"InChI":"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3","InChIKey":"PJMPHNIQZUBGLI-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)","Melting Point":"83-84","MolecularFormula":"C\u003csub\u003e22\u003c/sub\u003eH\u003csub\u003e28\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO","MolecularWeight":"336.5 g/mol","Pharmacodynamics":"Fentanyl produces strong analgesia through its activation of opioid receptors. It has a duration of action of several hours and a wider therapeutic index as patients develop tolerance to opioids. Fentanyl is associated with a risk of addiction and abuse and should not be mixed with alcohol or benzodiazepines.","Physical Description":"Solid","PrevSalts":["citrate","hydrochloride"],"PubChemId":3345,"Record Description":["Fentanyl is a monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid. It has a role as an opioid analgesic, a mu-opioid receptor agonist, an anaesthesia adjuvant, an intravenous anaesthetic, an adjuvant and an anaesthetic. It is a member of piperidines, an anilide and a monocarboxylic acid amide.","Fentanyl is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence. It is a Opiates substance.","Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like [morphine] and [oxycodone].  Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.  Fentanyl was FDA approved in 1968.","Fentanyl is an Opioid Agonist. The mechanism of action of fentanyl is as a Full Opioid Agonist.","Fentanyl is a synthetic, lipophilic phenylpiperidine opioid agonist with analgesic and anesthetic properties. Fentanyl selectively binds to and activates the mu-receptor in the central nervous system (CNS) thereby mimicking the effects of endogenous opiates. Activation of the mu-subtype opioid receptor stimulates the exchange of GTP for GDP on the G-protein complex and subsequently inhibits adenylate cyclase. This causes a decrease in intracellular cAMP which inhibits cAMP-mediated calcium influx into the cell via the calcium channels and thereby results in hyperpolarization and reduced neuronal excitability.","FENTANYL is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 6 approved and 38 investigational indications. This drug has a black box warning from the FDA.","A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)","A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)","See also: Fentanyl Citrate (has salt form); Fentanyl Hydrochloride (has salt form).","Fentanyl is a monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid. It has a role as an opioid analgesic, a mu-opioid receptor agonist, an anaesthesia adjuvant, an intravenous anaesthetic, an adjuvant and an anaesthetic. It is a member of piperidines, an anilide and a monocarboxylic acid amide.","LiverTox|Analgesic|Severe pain|Opiate"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Fentanyl","Name":"Fentanyl","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q407541","Name":"Fentanyl","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00813","Name":"Fentanyl","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3345","Name":"Fentanyl","Sub":false}]},{"Name":"ChemSpider","Urls":[{"Link":"https://www.chemspider.com/Chemical-Structure.3228.html","Name":"Fentanyl","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL596","Name":"Fentanyl","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119915","Name":"Fentanyl","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=437-38-7","Name":"Fentanyl","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014951","Name":"Fentanyl","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D00320","Name":"Fentanyl","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/UF599785JZ","Name":"Fentanyl","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9023049","Name":"Fentanyl","Sub":false}]}],"Reported Fatal Dose":"Minimum Lethal Dosage: Fentanyl 250 ug.","SMILES":"CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3","Salts":["citrate","hydrochloride"],"SaltsAcidCount":[0,1],"SaltsAmineCount":[1,1],"SaltsUNII":["MUN5LYG46H","59H156XY46"],"Scheduling":[{"gov":"Australia","schedule":"S8 substance"},{"gov":"Brazil","schedule":"Class A1 substance"},{"gov":"Canada","schedule":"Schedule I substance"},{"gov":"Germany","schedule":"Anlage III substance"},{"gov":"New Zealand","schedule":"Class B substance"},{"gov":"United Kingdom","schedule":"Class A substance"},{"gov":"United States","schedule":"Schedule II substance"},{"gov":"European Union","schedule":"prescription only substance"},{"act":"Single Convention on Narcotic Drugs 1961","gov":"United Nations","schedule":"Schedule I narcotic"}],"Solubility":"0.74mg/mL","StoreUNII":["UF599785JZ"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="70.115mm" version="1.2" viewBox="0 0 146.865 70.115" width="146.865mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="71.0" stroke="none" width="147.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="145.818" x2="138.198" y1="3.081" y2="16.279"/>
                  
            <line class="bond" id="mol1bnd2" x1="138.198" x2="122.958" y1="16.279" y2="16.279"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="122.254" x2="116.249" y1="17.499" y2="7.097"/>
                        
                <line x1="124.366" x2="118.36" y1="16.279" y2="5.878"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="116.249" x2="119.2515" y1="7.097000000000001" y2="12.298"/>
                <line class="hi" stroke="#FF0D0D" x1="118.36" x2="121.363" y1="5.878" y2="11.0785"/>
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="122.958" x2="117.453" y1="16.279" y2="25.815"/>
                  
            <line class="bond" id="mol1bnd5" x1="111.997" x2="100.098" y1="29.478" y2="29.478"/>
                  
            <line class="bond" id="mol1bnd6" x1="100.098" x2="92.478" y1="29.478" y2="16.27"/>
                  
            <line class="bond" id="mol1bnd7" x1="92.478" x2="77.238" y1="16.27" y2="16.27"/>
                  
            <line class="bond" id="mol1bnd8" x1="77.238" x2="71.731" y1="16.27" y2="25.815"/>
                  
            <line class="bond" id="mol1bnd9" x1="71.731" x2="77.238" y1="33.14" y2="42.686"/>
                  
            <line class="bond" id="mol1bnd10" x1="77.238" x2="92.478" y1="42.686" y2="42.686"/>
                  
            <line class="bond" id="mol1bnd11" x1="100.098" x2="92.478" y1="29.478" y2="42.686"/>
                  
            <line class="bond" id="mol1bnd12" x1="66.277" x2="54.378" y1="29.478" y2="29.478"/>
                  
            <line class="bond" id="mol1bnd13" x1="54.378" x2="46.758" y1="29.478" y2="42.676"/>
                  
            <line class="bond" id="mol1bnd14" x1="46.758" x2="31.518" y1="42.676" y2="42.676"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="23.898" x2="31.518" y1="55.884" y2="42.676"/>
                        
                <line x1="22.49" x2="28.703" y1="53.445" y2="42.676"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="23.898" x2="8.658" y1="55.884" y2="55.884"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="1.038" x2="8.658" y1="42.676" y2="55.884"/>
                        
                <line x1="3.853" x2="10.066" y1="42.676" y2="53.445"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="1.038" x2="8.658" y1="42.676" y2="29.468"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="23.898" x2="8.658" y1="29.468" y2="29.468"/>
                        
                <line x1="22.49" x2="10.066" y1="31.906" y2="31.906"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="31.518" x2="23.898" y1="42.676" y2="29.468"/>
                  
            <line class="bond" id="mol1bnd21" x1="117.453" x2="122.958" y1="33.14" y2="42.676"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="122.958" x2="115.33" y1="42.676" y2="55.879"/>
                        
                <line x1="124.366" x2="118.146" y1="45.114" y2="55.879"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="115.33" x2="122.95" y1="55.879" y2="69.077"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="122.95" x2="138.198" y1="69.077" y2="69.072"/>
                        
                <line x1="124.357" x2="136.791" y1="66.638" y2="66.634"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="138.198" x2="145.827" y1="69.072" y2="55.869"/>
                  
            <g class="bond" id="mol1bnd26">
                        
                <line x1="145.827" x2="138.207" y1="55.869" y2="42.671"/>
                        
                <line x1="143.011" x2="136.799" y1="55.869" y2="45.11"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd27" x1="122.958" x2="138.207" y1="42.676" y2="42.671"/>
                  
            <path class="atom" d="M117.597 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 -.0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM113.734 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.452q-.381 -.524 -1.208 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" fill="#FF0D0D" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M117.279 31.927h-.72l-2.62 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M71.559 31.927h-.72l-2.62 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm9" stroke="none"/>
                
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="117.453" x2="120.2055" y1="25.815" y2="21.047"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="111.997" x2="106.0475" y1="29.478" y2="29.478"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="71.731" x2="74.4845" y1="25.815" y2="21.0425"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="71.731" x2="74.4845" y1="33.14" y2="37.913"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="66.277" x2="60.3275" y1="29.478" y2="29.478"/>
            <line class="hi" id="mol1bnd21" stroke="#3050F8" x1="117.453" x2="120.2055" y1="33.14" y2="37.908"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Analgesics, Opioid; Adjuvants, Anesthesia; Narcotics; Anesthetics, Intravenous","Title":"Fentanyl","UNII":"UF599785JZ","Wikidata":"Q407541","Wikipedia":"Fentanyl","XLogP":4}